Health and Healthcare
Pfizer Ups Stock Buyback to $10 Billion
Published:
Last Updated:
In a sign that Pfizer Inc. (NYSE: PFE) has more cash on hand than the sense to use it wisely to create new drugs, its board approved a $10 billion share buyback. Pfizer has effectively cut costs, some via layoffs. R&D on new treatments is critical to the pharma company in a world of new age medicines, biotech and generics. Nonetheless, Pfizer believes it can increase shareholder returns by delivering cash the way that other public corporations like McDonald’s Corp. (NYSE: MCD) do. But a pharma company is not a fast-food chain.
The company announced:
The board of directors of Pfizer Inc. today declared a 24-cent third-quarter 2013 dividend on the company’s common stock, payable September 4, 2013, to shareholders of record at the close of business on August 2, 2013. The third-quarter 2013 cash dividend will be the 299th consecutive quarterly dividend paid by Pfizer.
In addition, the board of directors has authorized a new $10 billion share repurchase program to be utilized over time. This new program is in addition to the $3.9 billion of authorization remaining under the company’s current share repurchase program.
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
